This Small-cap Biotech Company Outperforms Pharma Giants like Lupin, Divis Lab and Sun Pharma with Multibagger Returns of 800 per cent!

The company has market cap of Rs 2,500 million (Rs 250 Crore) and Turnover (Runrate) of Rs 1,800 million (Rs 180 Crore).

Indrayani Biotech Ltd has outperformed pharma giant companies in the last 5 years turning out to be a blockbuster multibagger stock. As shown in the chart given below, the company has logged nearly 800 per cent of returns compared to Sun Pharmaceutical Industries Ltd gaining 326.98 per cent, Divis Laboratories Ltd jumped 247.21 per cent and Lupin Ltd given returns of 206.18 per cent.

Incorporated in 1992, Indrayani Biotech Ltd is in the business of Foods & Hospitality, Engineering and Healthcare.

In the Quarterly Results of June 2024, the company reported a revenue of Rs 31.53 crore. Net profit rose significantly to Rs 0.85 crore from loss of Rs 0.45 crore in the same period last year, reflecting a turnaround with 288 per cent growth on YoY basis. For the full financial year 2024, revenue reached all time high of  Rs 165 crore, up 1.7 per cent from Rs 162 crore in FY23. Net profit also grew to Rs 10 crore (Rs 100 million), up 16.12 per cent from Rs 7.9 crore in FY23. The company has reported 12 per cent of operating profit margin and 2 per cent of net profit margin.

In FY23-24 the company successfully comleted expansion of its pharma vertical also unlocked value of Dairy Business. The company added Vaasan Medical Center, KNISS Laboratories, Peekay Mediequip as its subsidiaries. Streamlining of new subsidiaries with strategic longterm investments resulting in reduced current profit. Filing of DRHP for SME-IPO with BSE for Dindigul Farm Product.

Indrayani Biotech Ltd has market cap of Rs 2500 million (Rs 250 Crore) and Turnover (Runrate) or Rs 1800 million (Rs 180 Crore).

Investors should keep an eye on this Small-Cap stock.

Disclaimer: The article is for informational purposes only and not investment advice.